Meredith Cook, who serves as Senior Vice President, General Counsel and Secretary at ANI Pharmaceuticals INC (NASDAQ:ANIP), completed a sale of 500 shares of the company's common stock on February 13, 2026. The shares were sold at $76.80 apiece, producing proceeds of $38,400.
Cook's Form 4 filing with the Securities and Exchange Commission shows she also disposed of shares on adjacent dates in connection with restricted stock vesting. According to the filing, 1,534 shares were withheld and disposed of on February 12 at a reported value of $76.70, totaling $117,657, and a further 1,779 shares were withheld and disposed of on February 14 at $77.36 each, totaling $137,623. The withholding was carried out for tax purposes related to the vesting of restricted stock awards.
The Feb. 13 sale was executed under a pre-established Rule 10b5-1 trading plan that Cook adopted on September 15, 2025. After accounting for these dispositions, Cook is recorded as directly owning 67,550 shares of ANI Pharmaceuticals.
Separately, ANI Pharmaceuticals disclosed preliminary financial metrics for 2025, providing a revenue range and updated profitability expectations. The company projected total net revenues between $854 million and $873 million for 2025 and indicated that adjusted non-GAAP EBITDA and adjusted non-GAAP EPS are expected to meet or exceed prior guidance. Management also signaled a growth trajectory, anticipating revenue to top $1 billion in 2026.
Market analysts responded to the company's updates. Guggenheim raised its price target for ANI Pharmaceuticals from $115.00 to $124.00 and maintained a Buy rating, reflecting the firm's view of the company's outlook.
ANI is also advancing its Rare Disease ophthalmology and retina strategy through the formation of the FutureVision Advisory Council. The council is intended to bolster the company's ophthalmology and retina franchise and is led by retina and uveitis specialists Arshad M. Khanani, MD, and Peter Chang, MD.
On the governance front, the company announced a board leadership change: director Patrick D. Walsh will retire from the Board of Directors after the 2026 Annual Meeting, and Thomas J. Haughey has been elected as the new Chairman.
From a market-data perspective, InvestingPro notes that ANI Pharmaceuticals carries a market capitalization of $1.66 billion and is trading below its Fair Value. InvestingPro's assessment of the company's financial health is labeled "GREAT," with a financial health score of 3.37. Investors are also reminded that ANI is scheduled to report earnings on February 27, and analysts maintain a bullish consensus on the stock, according to the referenced research notes.
This report summarizes the disclosed insider transactions and recent corporate updates as reflected in public filings and company announcements.